YHP1903

YHP1903 is an investigational drug developed by Yuhan Corporation. It has been evaluated in a randomized, open-label, single-dose, crossover Phase 1 clinical trial to assess its safety and pharmacokinetics in healthy volunteers. The specific mechanism of action, molecular target(s), modality (e.g., small molecule or biologic), and therapeutic indication for YHP1903 have not been disclosed in publicly available sources as of June 2025. The trial involved administration to healthy adults aged 19–55 years with a BMI between 18.5 and 30 kg/m²[1][4][8]. No information is available regarding its use in patients with specific diseases or conditions.